BiotechTube
Oxford BioTherapeutics

Oxford BioTherapeutics

Basel, Switzerland· Est.
oxfordbiotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $99.5M

Overview

Oxford BioTherapeutics is a clinical-stage oncology biotech leveraging its unique OGAP®-Verify proteomic discovery platform to identify novel membrane protein targets and develop first-in-class targeted therapies. The company has built a diversified pipeline with three clinical-stage assets and nine partnered programs, supported by six key industry partnerships. With over 50 employees and R&D sites in the UK and US, OBT employs a capital-efficient, partnership-centric business model to advance its innovative antibody-based therapeutics across multiple modalities.

Oncology

Technology Platform

OGAP®-Verify, a proprietary quantitative membrane proteomics platform that identifies and validates novel, cancer-specific cell surface targets from patient tissue samples for the development of antibody-based therapeutics.

Funding History

3
Total raised:$99.5M
Series C$48M
Series B$30M
Series A$21.5M

Opportunities

The rapidly expanding markets for ADCs, TCEs, and radiopharmaceuticals present a multi-billion dollar opportunity.
OBT's novel target discovery platform addresses a critical industry bottleneck, positioning it as a valuable partner for large pharma companies seeking to replenish pipelines.
Successful clinical data from its lead assets could trigger significant partnership deals or acquisition interest.

Risk Factors

High risk of clinical failure inherent to novel, first-in-class targets and complex therapeutic modalities.
Heavy reliance on partnerships for funding and development introduces dependency risk.
Intense competition in targeted oncology from larger, better-resourced companies could challenge market entry and differentiation.

Competitive Landscape

OBT competes in the crowded field of targeted oncology, facing large pharma (e.g., AstraZeneca, Pfizer, Roche) and biotechs (e.g., ImmunoGen, ADC Therapeutics) with advanced ADC/TCE platforms. Its key differentiator is its proprietary proteomic discovery engine focused on novel membrane targets, unlike many competitors who work on known targets or genomic-based discovery. It also competes with other platform companies like AbCellera or Biolojic Design in the antibody discovery space.

More companies in Antibody-Drug Conjugates →More companies in Switzerland →